Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Paclitaxel plus trastuzumab tested in node-negative HER2-positive breast cancer

US researchers test paclitaxel plus trastuzumab in node-negative HER2-positive breast cancer. In the image, light micrograph of breast cancer cells

Source: Dr Torsten Wittman / Science Photo Library

Study findings do not support trastuzumab-based chemotherapy in all breast cancer patients with small HER2-positive tumours, say researchers

There is no standard treatment for patients with small, node-negative HER2-positive breast cancer. In a study reported in The New England Journal of Medicine (online, 8 January 2015)[1], US researchers tested a regimen of adjuvant paclitaxel and trastuzumab in 406 such patients. Combination treatment was for 12 weeks followed by nine months of trastuzumab monotherapy.

The median follow-up period was 4.0 years and the three-year rate of survival free from invasive disease was 98.7% (95% confidence interval 97.6 to 99.8). There were 12 relapses, of which two were due to distant metastatic breast cancer, and the rate of serious adverse effects was low, with a heart failure incidence of 0.5%.

While the researchers say that patient outcomes were better than expected, they concede that their study does not support trastuzumab-based chemotherapy in all patients with small HER2-positive tumours.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067597

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmacy OSCEs

    Pharmacy OSCEs

    The only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested in your exams.

    £25.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.